ICU Medical, Inc. — Q2 2014 Form 10-Q
Business context and reporting period
Unaudited results for the quarter and six months ended June 30, 2014. ICU Medical develops, manufactures, and sells medical devices for infusion therapy, critical care, and oncology. It reported one business segment. Amounts below are in U.S. dollars; financial statement figures are in millions unless otherwise noted.
Financial performance and liquidity
- Revenue: Q2 revenue was $78.7 million, essentially unchanged from $78.7 million in Q2 2013. First-half revenue was $151.9 million, down 0.7% from $153.0 million.
- Profitability: Q2 gross profit was $37.5 million and gross margin 47.7%, versus $38.0 million and 48.4% a year earlier. Operating income fell to $8.7 million from $11.0 million; net income declined to $5.9 million from $7.4 million. Diluted EPS was $0.38 versus $0.48.
- First-half results: Gross profit was $73.6 million and gross margin 48.4%, compared with $74.8 million and 48.9% in 2013. Operating income was $18.6 million versus $23.0 million; net income was $12.5 million versus $16.1 million. Diluted EPS was $0.81 versus $1.06.
- Expenses: First-half SG&A increased to $46.8 million from $46.0 million; R&D rose to $8.2 million from $5.8 million. The effective tax rate was 34% in first-half 2014 versus 31% in 2013.
- Cash flow: First-half operating cash flow was $29.3 million, up from $26.0 million. Investing activities used $23.3 million, including $12.7 million of capital expenditures; financing activities provided $4.6 million. Cash and cash equivalents increased by $9.9 million to $236.0 million.
- Liquidity and debt: Cash, cash equivalents, and investment securities totaled $315.8 million at June 30, up from $296.9 million at year-end 2013. Current assets were $412.6 million and current liabilities $27.1 million. The balance sheet reports no debt line item. Management said available funds and expected operating cash flows should cover operations for at least the next 12 months.
Material changes and management commentary
- Q2 infusion therapy sales declined 2% to $55.3 million, mainly because domestic sales to Hospira fell $3.2 million; international infusion sales rose 13%. Critical care sales increased 8% to $13.7 million. Oncology sales were nearly flat at $9.3 million.
- For the first half, infusion therapy sales fell 3% to $106.1 million, with domestic Hospira sales down $7.5 million, partly offset by international growth. Critical care rose 6% to $26.8 million and oncology rose 5% to $18.3 million.
- Management attributed lower gross margin to unfavorable product mix and temporary rework on a product line, partly offset by lower logistics costs. Higher stock compensation and R&D staffing/project costs also contributed to expense growth.
- Hospira represented 36% of Q2 revenue and 35% of first-half revenue, down from 42% and 40%, respectively, in comparable 2013 periods. The filing identifies Hospira as a strategically important customer; its distribution agreements extend through most of 2018.
Outlook, risks, and unusual items
- In late July 2014, the company reorganized its U.S. commercial organization and reduced staff. It estimated a Q3 restructuring charge of approximately $3.0 million, primarily severance, and expected lower sales expenses thereafter.
- Estimated 2014 capital expenditures were $16–$19 million. The Salt Lake City plant expansion was completed in June; approximately $7 million was spent on it in the first half.
- Key risks include dependence on a concentrated customer base, particularly Hospira; customer ordering and inventory patterns; competition and product adoption; execution of product development and growth initiatives; foreign exchange exposure; and possible production, raw-material, regulatory, and litigation-related risks. The company did not hedge foreign currency exposures.
- The company held $79.9 million in investment securities, all described as investment grade. Management estimated that a 10% euro exchange-rate change would affect specified balance-sheet net assets by approximately $9.1 million. Routine legal proceedings were not expected to have a material adverse effect; indemnification agreements have no stated maximum, though management did not expect material liability.
- No material changes to previously disclosed risk factors were reported. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the lower domestic infusion sales to Hospira persist, and the pace of growth in international infusion, critical care, and oncology.
- Whether gross margin recovers after the product rework and mix effects, and whether higher R&D and SG&A produce expected growth.
- The actual Q3 restructuring charge and subsequent savings following the U.S. commercial reorganization.
- Capital spending against the $16–$19 million estimate and the operating contribution from the completed plant expansion.
- Customer concentration, foreign currency exposure, and the composition and liquidity of the investment portfolio.